



EYLEA[®] HD

(aflibercept) Injection 8 mg

EYLEA HD ICD-10-CM Billing and Coding Guide

March 2024 Update

The coding material discussed in this document is provided for informational purposes only, is subject to change, and should not be construed as legal advice.

The codes listed herein may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

ICD-10-CM = *International Classification of Diseases, 10th Revision, Clinical Modification.*

INDICATIONS

EYLEA[®] HD (aflibercept) Injection 8 mg is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- EYLEA HD is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA HD.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Codes for EYLEA HD

> CPT Code for Drug Administration*

Intravitreal injection of a pharmacologic agent (separate procedure)	67028
--	-------

> CPT Code Modifiers

Intravitreal injection of a pharmacologic agent (separate procedure): Indicates left eye injection	LT
Indicates right eye injection	RT
Indicates bilateral injection	50

Effective July 1, 2023, for CMS and most payers, the JZ modifier is required for reporting no discarded drug. Please see annotated sample CMS-1500 and CMS-1450 forms on pages 4-5 for information on how to submit claims with the JZ modifier and details on reporting no wastage.

*CPT codes, descriptions, and material are © 2024 American Medical Association. All rights reserved.
CMS = Centers for Medicare & Medicaid Services; CPT = Current Procedural Terminology.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Intravitreal injections, including those with aflibercept, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering EYLEA HD. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Codes for EYLEA HD (cont'd)

> HCPCS Code for EYLEA HD

Injection, aflibercept hd, 1 mg¹

J0177

> 10-Digit NDC for EYLEA HD

One EYLEA HD 8 mg (0.07 mL of a 114.3 mg/mL solution),
single-dose glass vial kit with injection components

6175505001 (Trade)
6175505051 (Sample)

> 11-Digit NDC for EYLEA HD

One EYLEA HD 8 mg (0.07 mL of a 114.3 mg/mL solution),
single-dose glass vial kit with injection components

61755005001 (Trade)
61755005051 (Sample)

Please check with your distributor for product availability.

Note: The product's NDC has been "zero-filled" to ensure creation of an 11-digit code that meets general billing standards. The zero-fill location is indicated in green.

HCPCS = Healthcare Common Procedure Coding System; NDC = National Drug Code.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA HD. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Sample CMS-1500 Form— Physician Office

Note: The information presented below is based on the paper claim format; please adopt this information to electronic equivalent fields in your software systems. The coding information discussed in this document and sample form is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed below may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

Box 19, Additional Claim Information

This box no longer needs to be populated.

Box 21, Diagnosis Code

Enter the appropriate ICD-10-CM code for the patient's diagnosis/condition; enter ICD indicator 0 for ICD-10-CM code(s).

Box 24A, NDC Information

Enter the NDC on the package used with the N4 qualifier and dosage based on measurement (mg, mL, etc.) (eg, **N461755005001** ML0.07). **Note:** Payer requirements differ on placement of the NDC code and N4 qualifier in the red shaded area. **Please check with your payer.***

Box 24D, Procedure Code

Enter the appropriate drug administration/CPT¹ code for EYLEA HD intravitreal injection: **67028**. Enter appropriate modifiers: **LT** for left eye injection, **RT** for right eye injection, or **50** for bilateral injection.

Box 24D, Product Code

Enter HCPCS code **J0177** to represent EYLEA HD.

Effective July 1, 2023, CMS and most payers require you to record drug waste. You can enter HCPCS code J0177 and use modifier JZ if zero drug was wasted (ie, J0177 JZ).

Box 24G, Units Administration

J0177 has a unit descriptor of 1 mg; report 8 units of the code when billing for an 8-mg injection of EYLEA HD (report 16 units when billing for bilateral 8-mg injections of EYLEA HD using 2 separate vials). **Note:** billing units may vary by payer. **Please check with your payer** for the appropriate billing units to be used.

*Some payers require the 10-digit NDC for EYLEA HD (6175505001 for the single-dose glass vial kit with injection components).

¹CPT copyright 2024 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association (AMA). Applicable FAR/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. FAR/DFARS = Federal Acquisition Regulation/Defense Federal Acquisition Regulation Supplement.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in the wet AMD study (PULSAR) from baseline through week 48 was 0.4% (3 out of 673) in the combined group of patients treated with EYLEA HD compared with 1.5% (5 out of 336) in patients treated with EYLEA 2 mg. The incidence in the DME study (PHOTON) from baseline to week 48 was 3.1% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 3.6% (6 out of 167) in patients treated with EYLEA 2 mg.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Sample CMS-1450 Form— Hospital Outpatient Department

Note: The information presented below is based on the paper claim format; please adopt this information to electronic equivalent fields in your software systems. The coding information discussed in this document and sample form is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed below may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

Boxes 42 and 43, Revenue Code

Enter the appropriate revenue code(s); enter the NDC on the package used with the N4 qualifier and dosage based on measurement (mg, mL, etc) (eg, **N461755005001** ML0.07). **Please Note:** Check with payer; NDC requirements and placement may vary.

Box 44, Procedure Code

Enter the appropriate drug administration/CPT* code for EYLEA HD intravitreal injection: **67028**. Include appropriate modifiers: **LT** for left eye injection, **RT** for right eye injection, or **50** for bilateral injection.

Product Code

Enter HCPCS code **J0177** to represent EYLEA HD.

Effective July 1, 2023, CMS and most payers require you to record drug waste. You can enter HCPCS code J0177 and use modifier JZ if zero drug was wasted (ie, J0177 JZ).

Box 46, Units


J0177 has a unit descriptor of 1 mg; report 8 units of the code when billing for an 8-mg injection of EYLEA HD (report 16 units when billing for bilateral 8-mg injections of EYLEA HD using 2 separate vials). **Note:** billing units may vary by payer. **Please check with your payer** for the appropriate billing units to be used.

Box 67, Diagnosis Code

Enter the appropriate ICD-10-CM code for the patient's diagnosis/condition.

Box 80, Remarks

This box no longer needs to be populated.



The image shows a sample CMS-1450 form with several callouts pointing to specific fields:

- Box 42 and 43:** Points to the Revenue Code field containing '610 Outpatient Clinic' and '636 N461755005001'.
- Box 44:** Points to the Procedure Code field containing '67028 RT' and 'J0177 JZ'.
- Box 46:** Points to the Units field containing '8'.
- Box 67:** Points to the Diagnosis Code field containing 'H40010'.
- Box 80:** Points to the Remarks field, which is empty.

*CPT copyright 2024 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association (AMA). Applicable FAR/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

- The most common adverse reactions ($\geq 3\%$) reported in patients receiving EYLEA HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters, vitreous detachment, corneal epithelium defect, and retinal hemorrhage.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.



Relevant ICD-10-CM Diagnosis Codes for EYLEA HD

Wet Age-Related Macular Degeneration (Wet AMD)

Exudative age-related macular degeneration	Right eye	Left eye	Bilateral	Unspecified eye
With active choroidal neovascularization	H35.3211	H35.3221	H35.3231	H35.3291
With inactive choroidal neovascularization	H35.3212	H35.3222	H35.3232	H35.3292
With inactive scar	H35.3213	H35.3223	H35.3233	H35.3293
Stage unspecified	H35.3210	H35.3220	H35.3230	H35.3290

Diabetic Macular Edema (DME)

Diabetes mellitus due to underlying condition with:	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	E08.3211	E08.3212	E08.3213	E08.3219
Moderate nonproliferative diabetic retinopathy with macular edema	E08.3311	E08.3312	E08.3313	E08.3319
Severe nonproliferative diabetic retinopathy with macular edema	E08.3411	E08.3412	E08.3413	E08.3419
Proliferative diabetic retinopathy with macular edema	E08.3511	E08.3512	E08.3513	E08.3519
Unspecified diabetic retinopathy with macular edema	E08.311			

Drug or chemical induced diabetes mellitus with:	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	E09.3211	E09.3212	E09.3213	E09.3219
Moderate nonproliferative diabetic retinopathy with macular edema	E09.3311	E09.3312	E09.3313	E09.3319
Severe nonproliferative diabetic retinopathy with macular edema	E09.3411	E09.3412	E09.3413	E09.3419
Proliferative diabetic retinopathy with macular edema	E09.3511	E09.3512	E09.3513	E09.3519
Unspecified diabetic retinopathy with macular edema	E09.311			

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS (cont'd)

- Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA HD and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Relevant ICD-10-CM Diagnosis Codes for EYLEA HD (cont'd)

> Diabetic Macular Edema (DME) (cont'd)

Type 1 diabetes mellitus with:

	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	E10.3211	E10.3212	E10.3213	E10.3219
Moderate nonproliferative diabetic retinopathy with macular edema	E10.3311	E10.3312	E10.3313	E10.3319
Severe nonproliferative diabetic retinopathy with macular edema	E10.3411	E10.3412	E10.3413	E10.3419
Proliferative diabetic retinopathy with macular edema	E10.3511	E10.3512	E10.3513	E10.3519
Unspecified diabetic retinopathy with macular edema	E10.311			

Type 2 diabetes mellitus with:

	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	E11.3211	E11.3212	E11.3213	E11.3219
Moderate nonproliferative diabetic retinopathy with macular edema	E11.3311	E11.3312	E11.3313	E11.3319
Severe nonproliferative diabetic retinopathy with macular edema	E11.3411	E11.3412	E11.3413	E11.3419
Proliferative diabetic retinopathy with macular edema	E11.3511	E11.3512	E11.3513	E11.3519
Unspecified diabetic retinopathy with macular edema	E11.311			

Other specified diabetes mellitus with:

	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	E13.3211	E13.3212	E13.3213	E13.3219
Moderate nonproliferative diabetic retinopathy with macular edema	E13.3311	E13.3312	E13.3313	E13.3319
Severe nonproliferative diabetic retinopathy with macular edema	E13.3411	E13.3412	E13.3413	E13.3419
Proliferative diabetic retinopathy with macular edema	E13.3511	E13.3512	E13.3513	E13.3519
Unspecified diabetic retinopathy with macular edema	E13.311			

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- EYLEA HD is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA HD.

WARNINGS AND PRECAUTIONS

- Intravitreal injections, including those with aflibercept, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering EYLEA HD. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Relevant ICD-10-CM Diagnosis Codes for EYLEA HD (cont'd)

> Diabetic Retinopathy (DR)

Diabetes mellitus due to underlying condition with:	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy without macular edema	E08.3291	E08.3292	E08.3293	E08.3299
Moderate nonproliferative diabetic retinopathy without macular edema	E08.3391	E08.3392	E08.3393	E08.3399
Severe nonproliferative diabetic retinopathy without macular edema	E08.3491	E08.3492	E08.3493	E08.3499
Proliferative diabetic retinopathy with traction retinal detachment involving the macula	E08.3521	E08.3522	E08.3523	E08.3529
Proliferative diabetic retinopathy with traction retinal detachment not involving the macula	E08.3531	E08.3532	E08.3533	E08.3539
Proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	E08.3541	E08.3542	E08.3543	E08.3549
Stable proliferative diabetic retinopathy	E08.3551	E08.3552	E08.3553	E08.3559
Proliferative diabetic retinopathy without macular edema	E08.3591	E08.3592	E08.3593	E08.3599
Unspecified diabetic retinopathy without macular edema	E08.319			

Drug or chemical induced diabetes mellitus with:	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy without macular edema	E09.3291	E09.3292	E09.3293	E09.3299
Moderate nonproliferative diabetic retinopathy without macular edema	E09.3391	E09.3392	E09.3393	E09.3399
Severe nonproliferative diabetic retinopathy without macular edema	E09.3491	E09.3492	E09.3493	E09.3499
Proliferative diabetic retinopathy with traction retinal detachment involving the macula	E09.3521	E09.3522	E09.3523	E09.3529
Proliferative diabetic retinopathy with traction retinal detachment not involving the macula	E09.3531	E09.3532	E09.3533	E09.3539
Proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	E09.3541	E09.3542	E09.3543	E09.3549
Stable proliferative diabetic retinopathy	E09.3551	E09.3552	E09.3553	E09.3559
Proliferative diabetic retinopathy without macular edema	E09.3591	E09.3592	E09.3593	E09.3599
Unspecified diabetic retinopathy without macular edema	E09.319			

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA HD. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Relevant ICD-10-CM Diagnosis Codes for EYLEA HD (cont'd)

> Diabetic Retinopathy (DR) (cont'd)

Type 1 diabetes mellitus with:	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy without macular edema	E10.3291	E10.3292	E10.3293	E10.3299
Moderate nonproliferative diabetic retinopathy without macular edema	E10.3391	E10.3392	E10.3393	E10.3399
Severe nonproliferative diabetic retinopathy without macular edema	E10.3491	E10.3492	E10.3493	E10.3499
Proliferative diabetic retinopathy with traction retinal detachment involving the macula	E10.3521	E10.3522	E10.3523	E10.3529
Proliferative diabetic retinopathy with traction retinal detachment not involving the macula	E10.3531	E10.3532	E10.3533	E10.3539
Proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	E10.3541	E10.3542	E10.3543	E10.3549
Stable proliferative diabetic retinopathy	E10.3551	E10.3552	E10.3553	E10.3559
Proliferative diabetic retinopathy without macular edema	E10.3591	E10.3592	E10.3593	E10.3599
Unspecified diabetic retinopathy without macular edema	E10.319			

Type 2 diabetes mellitus with:	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy without macular edema	E11.3291	E11.3292	E11.3293	E11.3299
Moderate nonproliferative diabetic retinopathy without macular edema	E11.3391	E11.3392	E11.3393	E11.3399
Severe nonproliferative diabetic retinopathy without macular edema	E11.3491	E11.3492	E11.3493	E11.3499
Proliferative diabetic retinopathy with traction retinal detachment involving the macula	E11.3521	E11.3522	E11.3523	E11.3529
Proliferative diabetic retinopathy with traction retinal detachment not involving the macula	E11.3531	E11.3532	E11.3533	E11.3539
Proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	E11.3541	E11.3542	E11.3543	E11.3549
Stable proliferative diabetic retinopathy	E11.3551	E11.3552	E11.3553	E11.3559
Proliferative diabetic retinopathy without macular edema	E11.3591	E11.3592	E11.3593	E11.3599
Unspecified diabetic retinopathy without macular edema	E11.319			

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in the wet AMD study (PULSAR) from baseline through week 48 was 0.4% (3 out of 673) in the combined group of patients treated with EYLEA HD compared with 1.5% (5 out of 336) in patients treated with EYLEA 2 mg. The incidence in the DME study (PHOTON) from baseline to week 48 was 3.1% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 3.6% (6 out of 167) in patients treated with EYLEA 2 mg.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

Relevant ICD-10-CM Diagnosis Codes for EYLEA HD (cont'd)

> Diabetic Retinopathy (DR) (cont'd)

Other specified diabetes mellitus with:	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy without macular edema	E13.3291	E13.3292	E13.3293	E13.3299
Moderate nonproliferative diabetic retinopathy without macular edema	E13.3391	E13.3392	E13.3393	E13.3399
Severe nonproliferative diabetic retinopathy without macular edema	E13.3491	E13.3492	E13.3493	E13.3499
Proliferative diabetic retinopathy with traction retinal detachment involving the macula	E13.3521	E13.3522	E13.3523	E13.3529
Proliferative diabetic retinopathy with traction retinal detachment not involving the macula	E13.3531	E13.3532	E13.3533	E13.3539
Proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	E13.3541	E13.3542	E13.3543	E13.3549
Stable proliferative diabetic retinopathy	E13.3551	E13.3552	E13.3553	E13.3559
Proliferative diabetic retinopathy without macular edema	E13.3591	E13.3592	E13.3593	E13.3599
Unspecified diabetic retinopathy without macular edema	E13.319			

The codes listed herein may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the service and products furnished to a specific patient.

Have a billing or reimbursement question related to EYLEA HD?

Reach out to your local Reimbursement Business Manager or call EYLEA4U[®] at 1-855-EYLEA4U (1-855-395-3248), Option 4, Monday–Friday, 9 AM–8 PM Eastern Time

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

- The most common adverse reactions (≥3%) reported in patients receiving EYLEA HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters, vitreous detachment, corneal epithelium defect, and retinal hemorrhage.
- Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA HD and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Please see additional Important Safety Information throughout and [click here](#) for the full Prescribing Information for EYLEA HD.

INDICATIONS

EYLEA® HD (aflibercept) Injection 8 mg is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- EYLEA HD is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA HD.

WARNINGS AND PRECAUTIONS

- Intravitreal injections, including those with aflibercept, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering EYLEA HD. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA HD. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in the wet AMD study (PULSAR) from baseline through week 48 was 0.4% (3 out of 673) in the combined group of patients treated with EYLEA HD compared with 1.5% (5 out of 336) in patients treated with EYLEA 2 mg. The incidence in the DME study (PHOTON) from baseline to week 48 was 3.1% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 3.6% (6 out of 167) in patients treated with EYLEA 2 mg.

ADVERSE REACTIONS

- The most common adverse reactions ($\geq 3\%$) reported in patients receiving EYLEA HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters, vitreous detachment, corneal epithelium defect, and retinal hemorrhage.
- Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA HD and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Please [click here](#) for the full Prescribing Information for EYLEA HD.

Reference: 1. Centers for Medicare & Medicaid Services. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations: fourth quarter, 2023 HCPCS coding cycle. Accessed February 13, 2024. <https://www.cms.gov/files/document/2023-hcpcs-application-summary-quarter-4-2023-drugs-and-biologicals-updated-02/05/2024.pdf>

REGENERON®

© 2024, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road, Tarrytown, NY 10591
02/2024 US.EHD.24.01.0154



EYLEA® HD
(aflibercept) Injection 8 mg

